The CEO of CTT Pharma has outlined significant corporate milestones in a letter to shareholders, detailing plans to transition to an SEC reporting company and begin manufacturing products using its patented micelle thin-film technology in 2026. This development is important as it signals a maturation phase for the company, potentially increasing transparency for investors and paving the way for commercializing innovative drug delivery methods that could improve patient convenience and efficacy.
The company is preparing to file an S-1 registration statement, which will enable access to funding through an equity line of credit. Becoming an SEC reporting entity is expected to bring additional transparency and attract a broader base of shareholders and investors. The capital raised is earmarked for manufacturing the company's technology, with the CEO emphasizing a mindful approach to share count and dilution.
CTT Pharma's immediate commercial focus is on bringing micelle-encapsulated vitamin and bioactive supplement strips, as well as nicotine oral strips, to manufacturing in 2026. The technology aims to offer better, faster, and more convenient oral drug delivery options. To support this, the company is strengthening its team with regulatory experts and individuals experienced in commercial product launches, and is actively seeking a manufacturing facility, with plans to identify a building in the first quarter of 2026.
A key aspect of the company's strategy involves navigating regulatory pathways for sales in North America. Concurrently, CTT Pharma is advancing its scientific credibility; a manuscript by Dr. Katharine Cole and founder Dr. Pankaj Modi on micelle and oral dissolvable strip technology has been accepted for publication on December 15, 2025. The company believes this publication will increase visibility and understanding of the science behind its platform, engaging shareholders, potential partners, and the scientific community.
The company's partnership with Johns Hopkins University, part of an NIH grant to develop a smoking cessation alternative using CTT's technology, awaits a funding decision for clinical trials. However, the CEO clarified that manufacturing and commercialization plans are independent of this timeline. Additionally, efforts are underway to strengthen the company's patent portfolio, with more details to be shared as they develop.
The planned transition to SEC reporting and the move toward manufacturing represent critical steps for CTT Pharma. For the pharmaceutical and supplement industries, successful commercialization of this drug delivery platform could introduce new product formats that enhance patient adherence and bioavailability. For investors, the increased regulatory oversight and transparency associated with becoming an SEC reporting company may reduce risk and provide clearer insights into corporate performance and strategy.
